Navigation Links
SpectraCell Laboratories Offers Additional Test for Heart Attack and Stroke Risk
Date:7/7/2008

HOUSTON, July 7 /PRNewswire/ -- SpectraCell Laboratories has added an innovative blood test called Lp-PLA2 (Lipoprotein-associated Phospholipase A2) to its arsenal of advanced cardiovascular testing aimed at early detection of cardiovascular disease. The new test measures the amount of a specific enzyme in blood that occurs when there is an active atherosclerotic process that could lead to the rupture of plaque and cause a heart attack or stroke.

Lipid measurement and cardiac imaging cannot identify which patients have rupture-prone plaque with thin fibrous caps. Therefore, finding serologic markers with high specificity for advanced plaque is a useful diagnostic tool in cardiovascular risk stratification. The Lp-PLA2 test helps physicians to identify patients who would benefit from more aggressive therapy and is especially recommended for intermediate and high-risk patients.

Once thought to be a simple process caused by the deposition of too much cholesterol in the arteries, atherosclerosis now appears to be a condition where the arterial lesions are inflamed, eventually leading to plaque rupture causing a heart attack or stroke. Lp-PLA2 is associated with a doubling of cardiovascular risk.

"What makes Lp-PLA2 so unique is that it is very specific to vascular inflammation, making it an excellent indicator of active atherosclerosis, which is otherwise difficult to detect through conventional methods," states Dr. Jan Troup, Ph.D., Director of Lipid Science at SpectraCell. "It tells a doctor that the risk of MI or stroke is higher due to developing vulnerable plaque. Doctors can use this information to modify treatment strategies determined by lipoprotein particles alone."

Since stroke is the leading cause of disability and third leading cause of death in America, early detection and prevention is key, especially since 68% of heart attacks and strokes occur from blood clots, not narrowing of the arteries.

Although Lp-PLA2 is an inflammatory marker, it is not affected by inflammation that might occur from infection or injury. This makes Lp-PLA2 a more specific marker than the more familiar CRP (C-Reactive Protein) which can be elevated from systemic infection, even when the vascular walls are healthy. High Lp-PLA2 in combination with high hs-CRP increases the risk level four fold.

Since 50% of all heart attacks occur in patients with normal cholesterol values, the Lp-PLA2 test is often used in conjunction with advanced lipoprotein tests. SpectraCell's LPP+(TM) combines advanced cholesterol testing with additional independent risk factors such as Lp-PLA2, hs-CRP, insulin and homocysteine. It is typically covered by standard insurance and Medicare.

About SpectraCell Laboratories -- SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing with the patent pending LPP(TM) (Lipoprotein Particle Profile) and FIA(TM) (Functional Intracellular Analysis) and tests.

SpectraCell's LPP(TM) testing is the most advanced lipoprotein test available. Unlike traditional cholesterol tests, SpectraCell's LPP(TM) directly measures the number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk.

SpectraCell's FIA(TM) testing is an innovative assessment of a patient's nutritional status. Unlike traditional serum, hair and urine tests, SpectraCell's FIA(TM) measures how an individual's white blood cells function in specific nutritional environments. Over 30 vitamins, minerals, amino acids and antioxidants are evaluated. As a result, individual differences in metabolism, age, genetics, health, prescription drug usage, absorption rate and other factors are taken into consideration.


'/>"/>
SOURCE SpectraCell Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Wei Sun, PhD, MD Joins SpectraCell Laboratories
2. Mesa Laboratories, Inc. Added to the Russell Microcap Index
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
4. Birchwood Laboratories Expands B-SURE™ Incontinence and Personal Care Product Line™; Three New Products Added Including B-SURE Fresh 'n Go™, B-SURE Bottom Balm™ and B-SURE Traveler™
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Nordic Naturals, Carlson Laboratories and Metagenics Announce Dismissal of Patent Infringement and Unfair Competition Suit
7. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
8. Advanced Instruments Anoxomat Mark II Anaerobic System is Excellent Alternative to Anaerobic Chambers, Gas Bags in Clinical Laboratories
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
10. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
11. Quest Diagnostics Chooses Roches Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown Health ... Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , The ... tax credit to individuals and corporations which donate directly to a “rural hospital” in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating ... new location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. ... Smart TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly ... for the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL ... KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016  In the ... projected to shift from systems dependent on CRTs monitors ... types of modality CRT Medical monitors and will ... are a host of foreseeable benefits to this ... will existing modalities have to be replaced in ...
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... Jersey , April 29, 2016 ... Suite for Life Sciences, Product Development Capabilities in ... Life Science Customer Base . ... provider, today announced the acquisition of Skura Corporation,s ... global leader in adaptive sales enablement technology for ...
Breaking Medicine Technology: